News

Keyword Search

Year

Sep 08, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Sept. 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to seventeen new employees as equity inducement awards outside of the Company's Amended and

Aug 26, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , Aug. 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to five new employees as equity inducement awards outside of the Company's Amended and Restated

Aug 25, 2021

CTI BioPharma and DRI Healthcare Trust Announce up to $135 Million Debt and Royalty Transaction

- Transaction to Fund Launch and Commercialization of Pacritinib in the United States This Year Pending FDA Approval, and Future Commercialization - SEATTLE and TORONTO , Aug. 25, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) (CTI) and DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U)

Aug 24, 2021

CTI BioPharma Announces Appointment of Diane Parks to Its Board of Directors

- Biopharma Commercial Leader Brings Significant Expertise Launching Novel Oncology Therapies - SEATTLE , Aug. 24, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks has overseen the launch of numerous

Aug 05, 2021

CTI BioPharma Reports Second Quarter 2021 Financial Results

- NDA for Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia Under Priority Review by FDA with PDUFA Target Action Date of November 30, 2021 - - Commercialization Activities on Track to Support a Potential Approval and Launch of Pacritinib in the United States in

Jul 29, 2021

CTI BioPharma to Report Second Quarter 2021 Financial Results on August 5, 2021

SEATTLE , July 29, 2021 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2021 financial results on Thursday, August 5, 2021 , after the close of the U.S. financial markets.

Jul 26, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , July 26, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated

Jul 09, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , July 8, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated

Jun 23, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , June 23, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

Jun 09, 2021

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , June 9, 2021 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Investors

News

News

–

–

–

–